DNDi E-news
February 2016   |   View Online

Chagas disease: Bridging the gap between patients and treatment


Viewpoint by Carolina Batista, Regional Medical Director, DNDi Latin America

Just before the end of 2015, the notorious announcement of the acquisition of benznidazole rights in the USA with the intention to apply for the FDA’s Priority Review Voucher (PRV) has generated innumerous debates and certainly has driven worldwide attention to Chagas. This state of affairs, despite all the buzz around KaloBios’s former CEO, has exposed the dramatic treatment access situation regarding the leading parasitic killer of the Americas. Currently, 99% of the estimated patients endure the lack of diagnostic and medical attention according to PAHO recommendations.»

Mycetoma: A critical step towards recognition as a neglected tropical disease

WHO Executive Board accepted a resolution to be tabled for adoption at the next World Health Assembly (WHA) in May to include mycetoma among the diseases termed ‘neglected tropical diseases’... »

DNDi and the Ministry of Health of the Government of Malaysia sign Memorandum of understanding on Hepatitis C

DNDi and the Ministry of Health of the Government of Malaysia have signed a Memorandum of Understanding to work together in order to develop a public health approach to Hepatitis C. The first step is to conduct clinical studies of promising new treatment regimens for Hepatitis C, which will be followed by scale-up of treatment for patients.»

Chagas: The Kissing Bug

Duámaco Escribano is infected with Chagas disease, a parasite born disease. In the indigenous community to which he belongs, the Koguis – one of the four ethnic groups living in the Sierra Nevada, on the north coast of Colombia – life is not measured in years: it starts with birth and ends with death, however long it may be…»

New diseases and new chemical entity enter DNDi project portfolio

In December 2015, DNDi published the latest version of the project portfolio as approved by the Board of Directors. This is the first portfolio resulting from DNDi’s new dynamic approach as developed in the new Business Plan (2015 – 2023) that was launched in September 2015.»

Scientific Articles

Antimicrobial Agents Chemotherapy
Validation and clinical evaluation of a novel method to measure miltefosine in leishmaniasis patients using dried blood spot sample collection »

Antimicrobial Agents Chemotherapy
Designing a paediatric study for an antimalarial drug including prior information from adults »

Journal of the International AIDS Society
Optimizing drugs to reach treatment targets for children and adolescents living with HIV »

Journal of Medicinal Chemistry
Novel amino-pyrazole ureas with potent in vitro and in vivo antileishmanial activity »

Punto de Vista: Carolina Batista »
História de vida: Duámaco Escribano »
El nuevo Director Ejecutivo de DNDi América Latina, Joël Keravec.»

Ponto de Vista: Carolina Batista »
História de vida: Duámaco Escribano »
O novo Diretor Executivo da DNDi América Latina, Joël Keravec.»


DNDi Innovation & Access - Partner`s Meeting 2016
Rio de Janeiro, 6-8 June 2016

World Leish 6
Toledo, 16-20 May 2017

DNDi and Instituto de Salud Carlos III are co-organizing World Leish 6


ASTMH in Kenya
Van Winkle`s: “Scientists are finally putting sleeping sickness to bed”

Huff Post RISE: "DNDi is the anti Martin Shkreli“

The Sun Daily: "Health Ministry conducting clinical studies to seek new treatment for victims of Hepatitis C"

BBC Brasil: “Como a indústria farmacêutica responde às doenças tropicais negligenciadas?”

NPR: “A Disease So Neglected It’s Not Even On ‘Most-Neglected’ Lists”

Global Health NOW: “The Untold Global Health Story of 2015: Mycetoma”

Business Times: “Paediatric HIV Treatment Implementation Study Begins in Kenya”

STAT: “How a system meant to develop drugs for rare diseases broke down”

Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2016 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202

Add us to your address book